EUVIMEDEUVIMED entdecken
Crossref

PSMA Radioligand Therapy: Success and Limitations to Date

Oliver Sartor

European Urology Focus · 2026-10 · 12 (5) · 825-826

DOI: 10.1016/j.euf.2026.07.010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Urology Focus, 2026-10. Verfasst von Oliver Sartor. Beteiligte Einrichtung: Transformational Prostate Cancer Research Center, LCMC Hospitals, New Orleans, Louisiana, United States. Electronic address: oliversartor@icloud.com. Die Arbeit nennt 10 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Transformational Prostate Cancer Research Center, LCMC Hospitals, New Orleans, Louisiana, United States. Electronic address: oliversartor@icloud.com.

Zitieren

APA

Sartor, O. (2026). PSMA Radioligand Therapy: Success and Limitations to Date. European Urology Focus, 12(5), 825-826. https://doi.org/10.1016/j.euf.2026.07.010

Vancouver

Sartor O. PSMA Radioligand Therapy: Success and Limitations to Date. European Urology Focus. 2026;12(5):825-826. doi:10.1016/j.euf.2026.07.010

BibTeX
@article{Sartor2026,
  author = {Sartor, Oliver},
  title = {PSMA Radioligand Therapy: Success and Limitations to Date},
  journal = {European Urology Focus},
  year = {2026},
  volume = {12},
  number = {5},
  pages = {825--826},
  doi = {10.1016/j.euf.2026.07.010}
}
Kostenlos starten →